Travere Therapeutics, Inc. (TVTX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

20/25

Growth 5 Margin 5 Expansion 4 Platform 2 Financial 4

latest quarter score

Earnings Reports

20
Travere Therapeutics (TVTX) Q2 2026: Filspari Sales Surge 96% on Strong FSGS Launch, Broadening Rare Kidney Franchise
August 05, 2026
19
TVTX Q1 2026: Filspari Revenue Jumps 88% as FSGS Approval Unlocks $3B Peak Sales Path
May 05, 2026
17
Travere Therapeutics (TVTX) Q4 2025: Filspari Sales Surge 144% as IGAN Adoption Broadens, FSGS Approval Path Remains in Focus
February 23, 2026
20
Travere Therapeutics (TVTX) Q3 2025: Filspari US Sales Surge 155% as FSGS Launch Readiness Accelerates
October 30, 2025
12
Verica Pharmaceuticals (TVTX) Q1 2025: WICAN Applicator Units Jump 16.7% as Leaner Model Drives Commercial Traction
July 07, 2025
15
Travere Therapeutics (TVTX) Q1 2025: Filspari Sales Surge 182% YoY, Setting Up FSGS Launch
July 04, 2025

Browse all companies